Free Trial

Nutex Health (NASDAQ:NUTX) Hits New 52-Week High After Analyst Upgrade

Nutex Health logo with Medical background

Shares of Nutex Health Inc. (NASDAQ:NUTX - Get Free Report) reached a new 52-week high during mid-day trading on Tuesday after Maxim Group raised their price target on the stock from $100.00 to $225.00. Maxim Group currently has a buy rating on the stock. Nutex Health traded as high as $184.28 and last traded at $176.21, with a volume of 192685 shares. The stock had previously closed at $174.71.

Separately, Benchmark boosted their target price on shares of Nutex Health from $150.00 to $300.00 and gave the stock a "buy" rating in a research note on Thursday, May 15th.

Read Our Latest Report on Nutex Health

Insiders Place Their Bets

In other Nutex Health news, CFO Jon Christian Bates purchased 1,000 shares of the firm's stock in a transaction that occurred on Tuesday, April 8th. The shares were acquired at an average cost of $81.81 per share, for a total transaction of $81,810.00. Following the completion of the purchase, the chief financial officer now owns 4,888 shares of the company's stock, valued at approximately $399,887.28. The trade was a 25.72% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 38.52% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE grew its position in shares of Nutex Health by 6,590.3% during the 4th quarter. Bank of America Corp DE now owns 2,074 shares of the company's stock worth $66,000 after buying an additional 2,043 shares during the period. Northern Trust Corp bought a new position in Nutex Health during the 4th quarter valued at $200,000. Baader Bank Aktiengesellschaft bought a new stake in shares of Nutex Health during the 4th quarter worth $206,000. Millennium Management LLC bought a new stake in shares of Nutex Health during the 4th quarter worth $213,000. Finally, World Investment Advisors bought a new stake in shares of Nutex Health during the 4th quarter worth $217,000. Institutional investors own 5.32% of the company's stock.

Nutex Health Stock Down 1.2%

The stock has a 50 day moving average price of $113.56 and a 200 day moving average price of $66.46. The company has a market capitalization of $890.28 million, a P/E ratio of -17.04 and a beta of -0.10. The company has a debt-to-equity ratio of 3.36, a quick ratio of 1.74 and a current ratio of 1.77.

Nutex Health (NASDAQ:NUTX - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported $2.56 EPS for the quarter, topping the consensus estimate of ($0.15) by $2.71. The company had revenue of $211.79 million during the quarter, compared to analyst estimates of $81.09 million. Nutex Health had a negative return on equity of 51.27% and a negative net margin of 14.09%.

Nutex Health Company Profile

(Get Free Report)

Nutex Health Inc operates as a physician-led, healthcare services, and operations company. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The PHM segment establishes and operates independent physician associations; and offers a cloud-based platform for healthcare organizations to provide value-based care and population health management.

Featured Stories

Should You Invest $1,000 in Nutex Health Right Now?

Before you consider Nutex Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nutex Health wasn't on the list.

While Nutex Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Defense Stocks Set to Crush the S&P This Summer
Analysts Are Watching These 4 Penny Stocks—You Should Too
Congress Is Pouring Millions Into These 6 Surprising Stocks

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines